Chromosomal region maintenance 1 (CRM1) can be a valid target in ovarian cancer and S109, a CRM1 inhibitor could be a potent anti-tumor agent for ovarian cancer treatment.


  • Many CRM1 inhibitors have been described previously but are irreversible but S109 is a reversible CRM1 inhibitor in ovarian cancer cells.
  • Cytoplasmic Foxo1 has been shown to be particularly high expression both in paclitaxel-resistant ovarian cancer cell lines and clinical samples and hence could be a molecular target for the treatment of sensitive or drug-resistant ovarian cancers.
  • A therapeutic strategy simultaneously targeting multiple oncogenic pathways or targets might be a rational and effective strategy in ovarian cancer.
Liu X, Chong Y, Liu H, Han Y, Niu M. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer. J Ovarian Res. 2015 Jun 10; 8(1):35.

Leave a Reply

Get DrBond

Stop Procrastinating. Start Bonding! Get the App on your phone to bond with the medical world, while on the go!
Apps StorePlay Store
What do you need help with?